Autori: Livingstone E
| Naslov | Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial (Article) |
| Autori | Livingstone E ... Kandolf-Sekulovic Lidija O ... Mijuskovic Zeljko P  ... (broj koautora 24)
|
| Info | EUROPEAN JOURNAL OF CANCER, (2023), vol. 190 br. , str. - |
| Projekat | F. Hoffmann-La Roche Ltd |
| Ispravka | Web of Science Članak Elečas Rang časopisa |
     |
